
#### WHO Guidelines: Grading evidence and developing evidencebased guidelines


Suzanne Hill
Training Course in Sexual and
Reproductive Health Research
Geneva, February 2009











Policy Makers and Health Professionals

to pilice mad



World Health Organization



#### What is a guideline?

 Medical guideline/clinical guideline, clinical practice guideline

"Systematically developed statements to assist practitioner and patient decisions about appropriate healthcare for specific clinical circumstances"

**Field & Lohr, 1992** 



#### Other terms


Clinical protocol/critical pathway/integrated care pathway

"Management recommendation based on a programmed description of the policy, containing well-defined choices regarding the policy to be followed, based on agreements between the disciplines involved."

Altena et al 1994



#### Why are they important?







#### We know what to do...

- Prescribe beta-blockers for patients after myocardial infarction
- Wash hands between patients
- Not prescribe antibiotics for viral upper respiratory tract infections
- Stop smoking....





# So to improve clinical decision making and quality of care...

- Clinical guidelines with:
  - Concrete aims and objective
  - Sufficient evidence to support most of the recommendations
  - Clear structure and attractive layout
  - Clear and specific recommendations
  - Taking account of norms and values
  - Applicable in different settings



#### So what is evidence?

- Stanford Encyclopedia of Philosophy
- The concept of evidence is central to both epistemology and the philosophy of science. Of course, 'evidence' is hardly a philosopher's term of art: it is not only, or even primarily, philosophers who routinely speak of evidence, but also lawyers and judges, historians and scientists, investigative journalists and reporters, as well as the members of numerous other professions and ordinary folk in the course of everyday life.
- And when we try to define 'evidence' ... we find it very difficult.
  - -R.G. Collingwood, The Idea of History



- Professional good intentions and plausible theories are insufficient for selecting policies and practices for protecting, promoting and restoring health.
- We will serve the public more responsibly and ethically when research designed to reduce the likelihood that we will be misled by bias and the play of chance has become an expected element of professional and policy making practice, not an optional add-on.

#### **Iain Chalmers**



How do we judge that we are sure that adherence to a recommendation will do more good than harm?



#### Does an intervention work?

Review: Prophylactic oxytocin for the third stage of labour Comparison: 01 Oxytocin versus no uterotonics (all trials) Outcome: 01 PPH (clinically estimated blood loss > or = 500 ml)

Study		Oxytocin n/N	Control n/N	Relative Risk (Fixed) 95% CI	Weight (%)	Relative Risk (Fixed) 95% CI
De	Groot 1996	25/78	55/143		10.2	0.83 [0.57, 1.22]
Hor	oward 1964	15/470	25/470		6.6	0.60 [0.32, 1.12]
× llan	ncheran 1990	0/5	0/5		0.0	Not estimable
No	ordstrom 1997	104/513	175/487	<del></del>	47.1	0.56 [0.46, 0.70]
Pie	erre 1992	37/488	126/482	-	33.3	0.29 [0.21, 0.41]
Poe	eschmann 1991	7/28	10/24		2.8	0.60 [0.27, 1.33]
Total e Test fo	95% CI) events: 188 (Oxytocin or heterogeneity chi-so or overall effect z=8.7	quare=18.10 df=4 p=0	.001 I³ =77.9%	•	100.0	0.50 [0.43, 0.59]
			0.1 0.2 Favours	2 0.5 1 2 5 Oxytocin Favours Contr	10 ol	



#### Does a screening test save lives?

Review: Screening for breast cancer with mammography Comparison: 01 Screening with mammography versus no screening Outcome: 01 Deaths ascribed to breast cancer, 7 years follow up

Study	Screening n/N	No screening n/N	Relative Risk (Fixed) 95% CI	Weight (%)	Relative Risk (Fixed) 95% CI	
11 Adequately randomise Canada 1980a	d trials 38/25214	28/25216		5.4	1.36 [0.83, 2.21]	
Canada 1980b	38/19711	39/19694	<del></del>	7.5	0.97 [ 0.62, 1.52 ]	
Malmö 1976	63/21088	66/21195	<del></del>	12.7	0.96 [ 0.68, 1.35 ]	
Subtotal (95% CI) fotal events: 139 (Screen fest for heterogeneity chi fest for overall effect z=(	-square=1.44 df=2		<b>*</b>	25.5	1.05 [0.83, 1.33]	
)2 Suboptimally randomis Göteborg 1982a	ed trials 6/10821	10/13101		1.7	0.73 [0.26, 2.00]	
Göteborg 1982b	21/9903	37/15708		5.5	0.90 [0.53, 1.54]	
Kopparberg 1977	71/39051	52/18846		13.5	0.66 [ 0.46, 0.94 ]	
Malmö II 1978	29/9581	33/8212		6.8	0.75 [ 0.46, 1.24 ]	
New York 1963	81/31000	124/31000		23.8	0.65 [ 0.49, 0.86 ]	
Stockholm 1981	53/38525	40/20651		10.0	0.71 [ 0.47, 1.07 ]	
Östergötland 1978	53/39034	67 <i>/</i> 37936	-	13.1	0.77 [ 0.54, 1.10 ]	
Subtotal (95% CI) Fotal events: 314 (Screen Fest for heterogeneity chi Fest for overall effect z=4	-square=1.51 df=8		•	74.5	0.71 [0.81, 0.83]	
Fotal (95% CI) Fotal events: 453 (Screen Fest for heterogeneity chi Fest for overall effect z=3	-square=10.12 df=8		•	100.0	0.80 [0.70, 0.91]	



### What makes children wear a bicycle helmet?

Review: Non-legislative interventions for the promotion of cycle helmet wearing by children

Comparison: 01 Non-legislative interventions vs control

Outcome: 02 Self-reported helmet ownership

Study	Treatment n/N	Control n/N		(Random) & CI	Weight (%)	Odds Ratio (Random) 95% CI
Br <del>itt</del> 1998	239/249	51/82		-	17.3	14.53 [ 6.70, 31.51 ]
Cushman 1991a	15/161	14/173	_	-	17.3	1.17 [ 0.54, 2.50 ]
Cushman 1991b	12/167	12/172		-	17.0	1.03 [0.45, 2.37]
Farley 1996	11/48	6/47	_	-	15.5	2.03 [0.68, 6.04]
Stutts 1990	6/67	7/54	-	<del></del>	15.1	0.66 [0.21, 2.10]
Towner 1992	26/98	23/81	-	<b>-</b>	17.8	0.91 [0.47, 1.76]
Total (95% CI) Total events: 309 (Treatmer Test for heterogeneity chi-s Test for overall effect z=1.0	square=37.95 df=5 p=<	609 0.0001 l² =86.8%		•	100.0	1.69 [0.65, 4.38]
			0.01 0.1 Favours control	10 Favours treatmer	100 it	



#### How would you grade that evidence?

Evidence	Recommendation	Organization
II-2	В	USPSTF
C+	1	ACCP
Strong	Strongly recommended	SIGN



# Recommendation for use of oral anticoagulation in patients with atrial fibrillation and mitral valve disease

Evidence	Recommendation	Organization
II-2	В	USPTSTF
C+	1	ACCP
Strong	Strongly recommended	SIGN



#### **Problem**

- Too many systems
- They only evaluate design
- No consideration of other important factors that influence judgements and recommendations



#### Why bother about grading?

- People draw conclusions about
  - Quality of evidence
  - Strength of recommendations
- Systematic explicit approaches help
  - Protect against errors
  - Resolve disagreements
  - Facilitate critical appraisal
  - Communicate information



#### What about WHO guidelines?



#### **GRADE**

# Grades of Recommendation Assessment Development and Evaluation



#### **Definitions**

#### **Quality of evidence**

the extent to which one can be confident that an estimate of effect or association is correct

#### Four categories

High ++++

Further research is very unlikely to change our confidence in the estimate of effect

Moderate +++

Further research is likely to have an important impact...

• Low ++

Further research is very likely to have an important impact.....

Very low +

Any estimate of effect is very uncertain




### The quality of evidence needs to be considered for each important outcome

- A review or guideline needs a clearly formulated question
  - Patients or population
  - Intervention
  - Comparison
  - Outcomes
- The quality of evidence may be different for different outcomes
- Decision makers (and review authors) need to consider the relative importance of outcomes



# Hierarchy of outcomes according to their importance to assess the effect of phosphate lowering drugs in patients with renal failure and hyperphosphatemia





#### Study design is important

- Early systems of grading the quality of evidence focused almost exclusively on study design
- Randomised trials provide, in general, far stronger evidence than observational studies.
  - Randomised trials start out at High
  - Observational studies start out at Low
- However, other factors may decrease or increase the quality of evidence



### Factors that may decrease the quality of evidence

- Study limitations
- Inconsistency of results
- Indirectness of evidence
- Imprecise results
- Reporting bias



## Factors that may increase the quality of evidence

- Large magnitude of effect
- A dose response relationship



#### **Quality assessment criteria**

Quality of evidence	Study design	Lower if	Higher if	
High	Randomised trial	Study quality: Serious	Strong association: Strong, no	
Moderate		limitations Very serious	plausible confounders	
Low	Observational study	limitations	Very strong, no major threats to	
Very low		Important inconsistency	validity	
		Directness: Some uncertainty Major	Evidence of a  Dose response  gradient	
		uncertainty	All plausible confounders	
		Sparse or imprecise data	would have reduced the effect	
		High probability of reporting bias		
				orld Health Organization

#### Strength of recommendation

The degree of confidence that the desirable effects of adherence to a recommendation outweigh the undesirable effects.



#### Desirable effects

- ·health benefits
- ·less burden
- ·savings

#### Undesirable effects

- ·harms
- ·more burden
- ·costs



#### **Categories of recommendations**

Although the degree of confidence is a continuum, we suggest using two categories: strong and weak.

- Strong recommendation: the panel is confident that the desirable effects of adherence to a recommendation outweigh the undesirable effects.
- Weak recommendation: the panel concludes that the desirable effects of adherence to a recommendation probably outweigh the undesirable effects, but is not confident.







#### **Determinants of strength of recommendation**

Factors	Impact on the strength of a recommendation
Balance between desirable and undesirable effects	Larger the difference between the desirable and undesirable effects, more likely a strong recommendation warranted. Narrower the gradient, more likely weak recommendation warranted.
Quality of the evidence	Higher the quality of evidence, more likely a strong recommendation warranted.
Values and preferences	More variability in values and preferences, or more uncertainty in values and preferences, more likely weak recommendation warranted.
Costs (resource use)	Higher the costs of an intervention – that is, the more resources consumed – less likely a strong recommendation warranted.



### Judgements about the strength of a recommendation

- No precise threshold for going from a strong to a weak recommendation
- The presence of important concerns about one or more of these factors make a weak recommendation more likely.
- Panels should consider all of these factors and make the reasons for their judgements explicit.
- Recommendations should specify the perspective that is taken (e.g. individual patient, health system) and which outcomes were considered (including which, if any costs).



### Implications of a strong recommendation

- Patients: Most people in your situation would want the recommended course of action and only a small proportion would not
- Clinicians: Most patients should receive the recommended course of action
- Policy makers: The recommendation can be adapted as a policy in most situations



### Implications of a weak recommendation

- Patients: The majority of people in your situation would want the recommended course of action, but many would not
- Clinicians: Be prepared to help patients to make a decision that is consistent with their own values
- Policy makers: There is a need for substantial debate and involvement of stakeholders



#### **Example**

- Post partum haemorrhage is the major cause of maternal mortality
- Effective interventions are available active management
- Which ones?
- Is one better than the other?
- Who should use them?



Should active management of the third stage of labour be used by skilled providers for all women to prevent post-partum haemorrhage?



	Quality assessment					Summary of findings						
		Qualit	y assessment			No of	patients		Effect			
No of studie s (Ref)	Desig n	Limitation s	Consistenc y	Directn ess	Other considerati ons	Active manage ment	Standard procedure s	Baseline Risk (95%CI)	Relative risk (95%CI)	NNT (95%CI)	Quality	Importanc e
Benefits	Benefits:											
Materna	l deaths											
0	-	-	-	-	-	-	-	i	-	-	-	8.5
Admissi	Admission to intensive care unit											
0	-	-	-	-	-	-	-	-	-	-	-	6.4
Blood Io	ss ≥ 500 m	ı										
4 PW 00 <sup>1</sup> Ad 97 Br 88 Du 90 Hi 98	RCT	serious limitation <sup>2,3,</sup> 17	no important inconsistenc y	some uncertai nty about directne ss <sup>4,5</sup>	none	3126	3158	min 8.3% (6.3, 10.3) max 17.9% (15.3, 20.5)	0.38 (0.32, 0.46)	min 8 (6.7, 11.2) max 16 (11.7, 24.7)		6.3
Blood Io	ss ≥ 1000 ı	ml										
4 PW 00 <sup>1</sup> Ad 97 Br 88 Du 90 Hi 98	RCT	serious limitation <sup>2,3,</sup> 17	no important inconsistenc y	some uncertai nty about directne ss <sup>4,5</sup>	none	3126	3158	min 1.5% (0.6-2.4) max 3.2% (2.0-4.4)	0.33 (0.21, 0.51)	min 41 (26.5, 90.1) max 73 (43.3, 225.5)		7.7
Need for	blood trar	sfusion				-	-					
5 PW 00 <sup>1</sup> Ad 97 Br 93 Br 88	RCT	minor limitation <sup>3,8</sup>	no important inconsistenc y	some uncertai nty about directne ss <sup>7</sup>	none	3229	3248	5.7% (4.1-7.2) <sup>16</sup>	0.34 (0.22, 0.53)	28 (18.7, 59,1) <sup>16</sup>		7.8
Du 90 Hi 98									11	day		
											World Orga	l Healt nizatio

		Qualit										
No of studie s (Ref)	Desig n	Limitation s	Consistenc y	Directn ess	Other considerati ons							
Benefits	Benefits:											
Materna	ernal deaths											
0	-	=	-	-	-							
Admission to intensive care unit												
0	-	-	-	-	-							
Blood loss ≥ 500 ml												
4 PW 00 <sup>1</sup> Ad 97 Br 88 Du 90 Hi 98	RCT	serious limitation <sup>2,3,</sup>	no important inconsistenc y	some uncertai nty about directne ss <sup>4,5</sup>	none							
Blood lo	ss ≥ 1000 ı	ml										
4 PW 00 <sup>1</sup> Ad 97 Br 88 Du 90 Hi 98	RCT serious no impor inconsist y		no important inconsistenc y	some uncertai nty about directne ss <sup>4,5</sup>	none							
Need for	r blood trar	sfusion										
5 PW 00 <sup>1</sup> Ad 97 Br 93 Br 88	RCT	minor limitation <sup>3,8</sup>	no important inconsistenc y	some uncertai nty about directne ss <sup>7</sup>	none							
Du 90 Hi 98												



manage ment	Standard procedure s	Baseline Risk (95%CI)	Relative risk (95%CI)	NNT (95%CI)	Quality	Importanc e 8.5
manage ment	procedure s	Risk (95%CI)	risk (95%CI)	(95%CI)	-	e 8.5
-	-	-				
-	-	-				
<u> </u>			-	-	-	6.4
3126	3158	min 8.3%				
		(6.3, 10.3) max 17.9% (15.3, 20.5)	0.38 (0.32, 0.46)	min 8 (6.7, 11.2) max 16 (11.7, 24.7)		6.3
3126	3158	min 1.5% (0.6-2.4) max 3.2% (2.0-4.4)	0.33 (0.21, 0.51)	min 41 (26.5, 90.1) max 73 (43.3, 225.5)		7.7
3229 3	3248	5.7% (4.1-7.2) <sup>16</sup>	0.34 (0.22, 0.53)	28 (18.7, 59,1) <sup>16</sup>		7.8
					World	l Healt nization

		Quality assessment						Summary of findings					
		No of patients Effect											
	No of studie s (Ref)	Desig n	Limitation s	Consistenc y	Directn ess	Other considerati ons	Active manage ment	Standard procedure s	Baseline Risk (95%CI)	Relative risk (95%CI)	NNT (95%CI)	Quality	Importanc e
	Benefits	: :											
	Materna	I deaths											
	0	-	-	-	-	-	-	-	-	-	-	-	8.5
	Admission to intensive care unit												
	0	-	-	-	-	-	-	-	-	-	-	-	6.4
	Blood loss ≥ 500 ml												
	4 PW 00 <sup>1</sup> Ad 97 Br 88 Du 90 Hi 98	RCT	serious limitation <sup>2,3,</sup> 17	no important inconsistenc y	some uncertai nty about directne ss <sup>4,5</sup>	none	3126	3158	min 8.3% (6.3, 10.3) max 17.9% (15.3, 20.5)	0.38 (0.32, 0.46)	min 8 (6.7, 11.2) max 16 (11.7, 24.7)		6.3
İ	Blood Id	ss ≥ 1000 r	ml					!					
	4 PW 00 <sup>1</sup> Ad 97 Br 88 Du 90 Hi 98	RCT	serious limitation <sup>2,3,</sup> 17	no important inconsistenc y	some uncertai nty about directne ss <sup>4,5</sup>	none	3126	3158	min 1.5% (0.6-2.4) max 3.2% (2.0-4.4)	0.33 (0.21, 0.51)	min 41 (26.5, 90.1) max 73 (43.3, 225.5)		7.7
4	Need fo	r blood trar	sfusion							•		•	
	5 PW 00 <sup>1</sup> Ad 97 Br 93 Br 88	RCT	minor limitation <sup>3,8</sup>	no important inconsistenc y	some uncertai nty about directne ss <sup>7</sup>	none	3229	3248	5.7% (4.1-7.2) <sup>16</sup>	0.34 (0.22, 0.53)	28 (18.7, 59,1) <sup>16</sup>		7.8
	Du 90 Hi 98											World Orgai	l Health nization

#### What would you recommend?

- Rate the importance of outcomes
- Check the quality of evidence
- Decide on your recommendation



#### What would you recommend?

 Active management of third stage of labour should be offered by skilled attendants to all women. (Strong recommendation, moderate quality evidence)



# Expertise needed for guideline development

- Literature search and analysis
- Epidemiology and biostatistics
- Healthcare research
- Clinical expert knowledge
- Social group processes
- Writing and editing of texts
- Production of guideline products



# Benefits and limitations of clinical guidelines

- Improving quality of care
- Improving information about optimal care
- Summary of research findings
- External accountability
- Basis for teaching and education
- Basis for interdisciplinary cooperation
- Contributing to efficient care
- Setting health care priorities

- Cookbook medicine
- Unrealistic expectations
- Loss of clinical autonomy
- Professional resistance and concern for legal consequences
- Misuse by governmental authorities
- Uncertainty about costeffectiveness
- Hidden political motives

Grol et al 2005



#### Implementation and behaviour change

Usually effective	Sometimes effective and sometimes not	Of little or no effect	Effectiveness unknown
Outreach visits	Audit and feedback	Educational materials	Financial stimuli
Decision support, reminders	Efforts of opinion leaders	Courses, conferences	Administrative or organisational interventions
Interactive education	Local consensus meetings		
Multifaceted interventions	Patient oriented interventions		
Mass media interventions			

Bero et al, 1998



#### Summary

- Evidence is a tough taskmaster
- Systematic reviews and critical appraisal essential
- Content experts alone insufficient
- Transparent system required
- Judgements should be explicit
- To make it worth while, implementation and evaluation have to be integral to process



